Hutchmed (China) Limited (HCM) ORD USD0.10
- Add to watchlist
- Create an alert
- This stock can be held in a
296.00p
302.00p
353.00p
£2.49 bn
300.00p
292.00p
190.40p
32.65
0.00p (0.00%) Previous:
0.00p
75,008
n/a
1,000
Performance
1 week 1W | 0.67% | 1 year 1Y | 11.94% |
---|---|---|---|
1 month 1M | 20% | 2 years 2Y | 92.8% |
3 months 3M | 17.65% | 3 years 3Y | 38.65% |
6 months 6M | 6.38% | 5 years 5Y | 8.7% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue ($m) | 838.00 | 426.41 |
Profit before tax ($m) | 58.31 | (410.42) |
Adjusted EPS (¢): | 12.00 | (43.00) |
P/E ratio | 30.80 | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: US dollar
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Hutchmed partner Takeda gets Japanese approval for Fruzaqla
24 September 2024 11:06
-
Hutchmed to present new and updated clinical trial data
9 September 2024 12:31
-
Hutchmed withdraws supplemental new drug application in China
30 August 2024 10:53
-
Japan Approval for FRUZAQLA
24 September 2024 08:00
-
Total Voting Rights
30 August 2024 09:30
-
Update on Fruquintinib for Gastric Cancer in China
30 August 2024 07:00
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.